Andy Studna, Senior Editor

Increased use of fentanyl underscores immediate need for better testing methods.

New research initiative will investigate the potential of zanidatamab as a monotherapy and in combination with other treatments for patients with different tumor types and stages.

Ongoing phase 1 dose-escalation trial of KO-2806 (FIT-001) for the treatment of patients with KRASG12C-mutated non-small cell lung cancer expected to begin dosing patients in combination with adagrasib by mid-2024.

New laws leave consumers unprotected against third parties accessing their genetic data.

Exagamglogene autotemcel (exa-cel) has shown the potential to be a landmark therapy in preventing episodes of excruciating pain among patients with sickle cell disease.

Insightful sound bytes from KOLs attending SCOPE EUROPE 2023.

Interactive panel discussed the evolving area of data transfer and the usage of EHR-to-EDC.

Industry leaders gathered to address the current landscape of data collection in clinical trials.

In an interview at SCOPE Europe 2023 with Applied Clinical Trials Editor, Andy Studna, Tony Mikulaschek, VP, eCOA, IQVIA Technologies addresses what stakeholders should be thinking of in the data collection space moving forward.

In an interview at SCOPE Europe 2023 with Applied Clinical Trials Editor, Andy Studna, Tony Mikulaschek, VP, eCOA, IQVIA Technologies discusses how regulatory bodies are currently viewing the data collection space.

In an interview at SCOPE Europe 2023 with Applied Clinical Trials Editor, Andy Studna, Tony Mikulaschek, VP, eCOA, IQVIA Technologies discusses how eCOAs are being applied to clinical trials.

With so many new solutions and other technologies appearing in the clinical trials space, how are stakeholders choosing which ones are best for them and how are these advancements translating to the actual clinic?

While clinical research in rare diseases has many unique operational challenges, there is plenty of work being done to advance it and bring effective therapies to patients.

Bingham discusses the logistical challenges associated with coordinating patient involvement in rare disease clinical trials.

Amy Cramer, steering committee board co-chair, HL7 FHIR Accelerator Vulcan, gives an overview of Vulcan at the 2023 DPHARM conference in Boston, MA.

Amy Cramer, steering committee board co-chair, HL7 FHIR Accelerator Vulcan, shares what she is currently seeing in the data space of clinical trials at the 2023 DPHARM conference in Boston, MA.

How can industry bring its latest technologies together?

Colleen Hoke, co-founder and CEO, ObjectiveHealth discusses what the future of patient recruitment could look like at the 2023 DPHARM conference in Boston, MA.

Colleen Hoke, co-founder and CEO, ObjectiveHealth discusses the challenges industry is currently seeing in patient recruitment at the 2023 DPHARM conference in Boston, MA.

ObjectiveHealth presents real-world case study on enrollment solutions in DPHARM 2023 session.

With the recent boom in artificial intelligence (AI), industry is finding ways to best utilize it in advancing the development of potential therapies.

New models such as IROs are changing the way industry views the current site landscape and addressing challenges.

Innovative pharma companies are stepping up to integrate digital health technology to advance pharmaceutical drug and medical device development, in both the healthcare and research worlds, to achieve better measurements and outcomes.

Raj Indupuri, CEO and co-founder of eClinical Solutions discusses the trends he is seeing with artificial intelligence in the clinical trials space.

The evolution of data and digital health uses in both the healthcare and research worlds is bringing the two closer together for the good of patients.

Integrated research organizations (IROs) are creating a shift in the way clinical trials are operated, bringing new methods for enrollment and building patient-physician relationships.

In this Q&A, Jimmy Bechtel, MBA, VP of site engagement, Society for Clinical Research Sites discusses evolving challenges in the site landscape, what SCRS is doing to alleviate burden, as well as the organization’s upcoming event, the Global Site Solutions Summit in October 2023.

From startups to major research organizations, early-phase research can be managed in different ways depending on the company.

DIA session focuses on the ins and outs of returning individual participant data.

DIA session highlights strategies for stakeholders to make clinical trials more inclusive for diverse populations.